- Home
- RXST vs PROK Comparison
RXST vs PROK Comparison
Compare RXST & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXST | PROK |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.0M | 296.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RXST | PROK |
|---|---|---|
| Price | $7.37 | $1.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $9.78 | $7.40 |
| AVG Volume (30 Days) | 593.6K | ★ 897.5K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,479,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $5.90 | $0.54 |
| 52 Week High | $16.73 | $7.13 |
Technical Indicators
Market Signals| Indicator | RXST | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 45.93 |
| Support Level | $7.27 | $1.71 |
| Resistance Level | $7.72 | $2.58 |
| Average True Range (ATR) | 0.36 | 0.11 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 64.06 | 30.00 |
Price Performance
Historical ComparisonAbout RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.